NDATOPICALCREAM
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOFADE is a topical cream formulation of oxymetazoline hydrochloride, a selective alpha-1 adrenergic agonist approved by the FDA in January 2017. It is indicated for the treatment of persistent facial erythema (redness) associated with rosacea in adults. The drug works by causing vasoconstriction of blood vessels in the skin, thereby reducing visible redness and flushing.
$0.003BPart D
PeakStable
8.6 years to LOEProduct is in peak commercial phase with modest Medicare utilization; team size likely stable with focus on maintenance and market penetration rather than rapid growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
Started Apr 2019
1,105 enrolled
Rosacea
Career Relevance
RHOFADE offers stable career opportunities in commercial and medical affairs roles, though limited job openings suggest a lean, mature team structure. The product's established market position and lack of competitive threats create predictable but not high-growth career trajectories, making it suitable for professionals seeking stability over rapid advancement.
Brand Manager
Worked on RHOFADE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.